Meds & supplements › Aficamten
Medicine
MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗
WARNING: RISK OF HEART FAILURE MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is <50% and ≥40%. Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction. Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program. WARNING: RISK OF HEART FAILURE See full prescribing information for complete boxed warning. MYQORZO can cause heart failure due to systolic dysfunction. Echocardiogram assessments of left ventricular ejection fraction (LVEF) are required before and during MYQORZO use. Initiation in patients with left ventricular ejection fraction (LVEF) <55% is not recommended. Decrease dose if LVEF <50% and ≥40%. Interrupt dosing if LVEF <40% or if worsening clinical status. MYQORZO is available only through a restricted program called the MYQORZO REMS Program.
MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
MYQORZO can cause serious side effects, including: Heart failure, a condition where the heart cannot pump with enough force. Heart failure is a serious condition that can lead to death. You must have echocardiograms before and during treatment with MYQORZO and monitor for signs and symptoms of heart failure. People who develop a serious illness such as a serious infection or who develop a new or worsening irregular heartbeat have a greater risk of heart failure during treatment with MYQORZO.
Tell your healthcare provider or get medical help right away if you develop new or worsening: shortness of breath swelling in your legs a racing sensation in your heart (palpitations) fatigue chest pain rapid weight gain The risk of heart failure is also increased when MYQORZO is taken with certain other medicines. Tell your healthcare provider about the medicines you take, both prescribed and obtained over-the-counter, before and during your treatment with MYQORZO.
Because of the risk of heart failure, MYQORZO is only available through a restricted distribution program called the MYQORZO Risk Evaluation and Mitigation Strategy (REMS) Program. Your healthcare provider must be enrolled in the MYQORZO REMS Program for you to be prescribed MYQORZO. Before you start treatment with MYQORZO, you must enroll in the MYQORZO REMS Program.
Talk to your healthcare provider about how to enroll in the program. You will be given information about the program when you enroll. Before you take MYQORZO, your healthcare provider and pharmacist will make sure you understand how to take MYQORZO safely, which will include returning for echocardiograms when advised by your healthcare provider.
MYQORZO can only be dispensed by a certified pharmacy that participates in the MYQORZO REMS Program. Your healthcare provider can give you information on how to find a certified pharmacy. If you have any questions about the MYQORZO REMS Program, ask your healthcare provider, go to www.MYQORZOREMS.com, or call 1-844-285-7367.
See "
Take MYQORZO exactly as your healthcare provider tells you to take it. Do not change your dose of MYQORZO without talking to your healthcare provider first. Take MYQORZO 1 time a day, at about the same time each day, Take MYQORZO with or without meals. Swallow the MYQORZO tablet whole. If you miss a dose of MYQORZO, take it as soon as possible and take your next dose at your regularly scheduled time the next day.
Do not take 2 doses on the same day to make up for a missed dose. Your healthcare provider may change your dose or temporarily stop your treatment with MYQORZO if you have certain side effects. If you take too much MYQORZO, call your healthcare provider or Poison Control Help Line at 1-800-222-1222 or go to the nearest hospital emergency room right away.
What are the possible side effects of MYQORZO? MYQORZO can cause serious side effects including: Heart failure. The most common side effect of MYQORZO is high blood pressure (hypertension). Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Cytokinetics at 1-833-633-2986.
" for information about side effects. What is MYQORZO? MYQORZO is a prescription medicine used to treat adults with symptomatic obstructive cardiomyopathy (oHCM) to improve functional capacity and symptoms. It is not known if MYQORZO is safe and effective in children.
Do not take MYQORZO if you take a medicine called rifampin. Before taking MYQORZO, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant. It is not known if MYQORZO can cause harm to your unborn baby. Tell your healthcare provider if you become pregnant during treatment or within 3 weeks after the last dose of MYQORZO.
There is a pregnancy safety study for MYQORZO. Your healthcare provider should report your pregnancy exposure to Cytokinetics, Inc. are breastfeeding or plan to breastfeed. It is not known if MYQORZO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with MYQORZO.
Before and during MYQORZO treatment, tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking MYQORZO with certain medicines may lead to increased levels of MYQORZO in your blood and increase your risk of heart failure.
Do not stop or change the dose of a medicine or start a new medicine without telling your healthcare provider. Especially tell your healthcare provider if you take the medicines: fluconazole (if used for more than 3 days) voriconazole fluvoxamine
Store MYQORZO at room temperature between 68°F to 77°F (20°C to 25°C). MYQORZO comes in a bottle with a child-resistant closure. Keep MYQORZO and all medicines out of the reach of children.
sofidex [Internet]. Daloreum; c2026. Aficamten; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/aficamten
sofidex. (2026, August 2). Aficamten. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/aficamten
Aficamten. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/aficamten
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.